StockNews.AI
VTRS
StockNews.AI
146 days

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris – VTRS

1. Faruqi & Faruqi is investigating claims against Viatris (VTRS). 2. Viatris missed financial estimates for Q4 2024 and 2025 guidance. 3. Stock fell 15.21%, closing at $9.53 following poor results. 4. Remediation efforts at a manufacturing facility are ongoing. 5. Potential legal claims could impact investors and stock price.

4m saved
Insight
Article

FAQ

Why Bearish?

VTRS's recent poor earnings report and missed guidance lead to a significant stock drop, similar to past earnings misses that diminished investor confidence.

How important is it?

The investigation into claims and the stock's significant drop indicates serious investor concern, likely affecting future price performance.

Why Short Term?

The immediate concern is the stock price reaction to missed estimates and potential litigation, impacting VTRS in the coming months.

Related Companies

PFEABBVJNJ
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was "more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility." On this news, Viatris's stock price fell $1.71 per share, or 15.21%, to close at $9.53 per share on February 27, 2025. To learn more about the Viatris Inc. investigation, go to www.faruqilaw.com/VTRS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/4c96193e-9e8a-4e5d-878a-3e41b441e24a

Related News